Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EP102 in advanced solid tumors
NL-OMON60182Phase 1Recruiting
- Sponsor
- EPICS Therapeutics
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, single-arm trial of EP102 in Nonhematologic neoplasms, sponsored by EPICS Therapeutics. Primary endpoint: Primary endpoint(s). Started Apr 2026; status: recruiting.
02
Drugs
EP102
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON60182.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60182.